



ELSEVIER

Diabetes Research and Clinical Practice 43 (1999) 211–213

DIABETES RESEARCH  
AND  
CLINICAL PRACTICE

## Author index of volume 43

- Aarons, J.H., see Dorman, J.S. 43, 41  
Ahmad Laway, B., see Hamid Zargar, A. 43, 67  
Albala, C., see Santos, J.L. 43, 143
- Battell, M.L., see Yuen, V.G. 43, 9  
Baynes, J.W., see Degenhardt, T.P. 43, 81  
Bowen, K., see Scott, R. 43, 179  
Burke, J.P., see Dorman, J.S. 43, 41  
Burt, M.J., see Florkowski, C.M. 43, 199
- Calvillán, M., see Santos, J.L. 43, 143  
Campbell, L., see Scott, R. 43, 179  
Carrasco, E., see Santos, J.L. 43, 143  
Castell, C., R. Tresserras, J. Serra, A. Goday, G. Lloveras, L. Salleras, Prevalence of diabetes in Catalonia (Spain): an oral glucose tolerance test-based population study 43, 33  
Chambers, S.T., see Dellow, W.J. 43, 91  
Cheah, J.S., see Ng, W.Y. 43, 127  
Chen, C.J., see Chen, K.T. 43, 101  
Chen, K.T., C.J. Chen, M.M.-T. Fuh, K.M.V. Narayan, Causes of death and associated factors among patients with non-insulin-dependent diabetes mellitus in Taipei, Taiwan 43, 101  
Cruickshanks, K.J., see Dorman, J.S. 43, 41
- Dawson, P., see McGrath, N.M. 43, 205  
Degenhardt, T.P., M.-X. Fu, E. Voss, K. Reiff, R. Neidlein, K. Strein, S.R. Thorpe, J.W. Baynes, R. Reiter, Aminoguanidine inhibits albuminuria, but not the formation of advanced glycation end-products in skin collagen of diabetic rats 43, 81  
Dellow, W.J., S.T. Chambers, M. Lever, H. Lunt, R.A. Robson, Elevated glycine betaine excretion in diabetes mellitus patients is associated with proximal tubular dysfunction and hyperglycemia 43, 91  
Dorman, J.S., J.P. Burke, B.J. McCarthy, J.M. Norris, A.R. Steenkiste, J.H. Aarons, R. Schmeltz, K.J. Cruickshanks, Temporal trends in spontaneous abortion associated with Type 1 diabetes 43, 41
- Faridah, I., see Wan Nazaimoon, W.M. 43, 59  
Florkowski, C.M., P.M. George, J.A. Willis, M.K. Stott, M.J. Burt, J.D. Upton, J. Nesbit, T.A. Walmsley, R.S. Scott, Haemochromatosis gene mutations Cys282Tyr and His63Asp are not increased in Type 2 diabetic patients compared with the Canterbury (New Zealand) general population 43, 199  
Fuh, M.M.-T., see Chen, K.T. 43, 101  
Fukuzawa, M., J. Satoh, X. Qiang, S. Miyaguchi, Y. Sakata, T. Nakazawa, F. Ikehata, S. Ohta, T. Toyota, Inhibition of tumor necrosis factor- $\alpha$  with anti-diabetic agents 43, 147  
Fu, M.-X., see Degenhardt, T.P. 43, 81  
Furukawa, K., see Isotani, H. 43, 173
- George, P.M., see Florkowski, C.M. 43, 199  
Goday, A., see Castell, C. 43, 33
- Hall, D.A., see Sansom, S.C. 43, 21  
Hamid Zargar, A., A. Iqbal Wani, S. Rashid Masoodi, B. Ahmad Laway, M. Iftikhar Bashir, Mortality in diabetes mellitus—data from a developing region of the world 43, 67  
Hänninen, J., J. Takala, S. Keinänen-Kiukaanniemi, Albuminuria and other risk factors for mortality in patients with non-insulin-dependent diabetes mellitus aged under 65 years: a population-based prospective 5-year study 43, 121  
Harada, N., A. Kashiwagi, Y. Nishio, R. Kikkawa, Effects of cholesterol-lowering treatments on oxidative modification of plasma intermediate density lipoprotein plus low density lipoprotein fraction in Type 2 diabetic patients 43, 111  
Heinemann, L., see Overmann, H. 43, 137  
Hew, F.L., see Wan Nazaimoon, W.M. 43, 59  
Huang, W.-C., see Marbury, T. 43, 155
- Iftikhar Bashir, M., see Hamid Zargar, A. 43, 67  
Ikeda, T., K. Iwata, Y. Tanaka, Long-term effect of epalrestat on cardiac autonomic neuropathy in subjects with non-insulin dependent diabetes mellitus 43, 193  
Ikehata, F., see Fukuzawa, M. 43, 147

- Inukai, T., see Tayama, K. 43, 49  
 Iqbal Wani, A., see Hamid Zargar, A. 43, 67  
 Ismail, I.S., see Wan Nazaimoon, W.M. 43, 59  
 Isotani, H., Y. Nakamura, K. Kameoka, K. Tanaka, K. Furukawa, H. Kitaoka, N. Ohsawa, Pulmonary diffusing capacity, serum angiotensin-converting enzyme activity and the angiotensin-converting enzyme gene in Japanese non-insulin-dependent diabetes mellitus patients 43, 173  
 Iwata, K., see Ikeda, T. 43, 193
- Kameoka, K., see Isotani, H. 43, 173  
 Kashiwagi, A., see Harada, N. 43, 111  
 Keinänen-Kiukaanniemi, S., see Hänninen, J. 43, 121  
 Khalid, B.A.K., see Wan Nazaimoon, W.M. 43, 59  
 Kikkawa, R., see Harada, N. 43, 111  
 Kitaoka, H., see Isotani, H. 43, 173  
 Kohgo, Y., see Moriya, M. 43, 187
- Lalitha, S., see Vijay, V. 43, 167  
 Lebovitz, H., see Marbury, T. 43, 155  
 Letchuman, R., see Wan Nazaimoon, W.M. 43, 59  
 Lever, M., see Dellow, W.J. 43, 91  
 Lintott, C.J., see Scott, R. 43, 179  
 Li, W.M., see Yuen, V.G. 43, 9  
 Lloveras, G., see Castell, C. 43, 33  
 Lui, K.F., see Ng, W.Y. 43, 127  
 Lunt, H., see Dellow, W.J. 43, 91
- Marbury, T., W.-C. Huang, P. Strange, H. Lebovitz, Repaglinide versus glyburide: a one-year comparison trial 43, 155  
 May, J.M., see Vincent, T.E. 43, 1  
 McCarthy, B.J., see Dorman, J.S. 43, 41  
 McGrath, N.M., G.N. Parker, P. Dawson, Early presentation of type 2 diabetes mellitus in young New Zealand Maori 43, 205  
 McNeill, J.H., see Yuen, V.G. 43, 9  
 Mehta, P., see Sansom, S.C. 43, 21  
 Mendiratta, S., see Vincent, T.E. 43, 1  
 Miyaguchi, S., see Fukuzawa, M. 43, 147  
 Moriya, M., T. Okumura, N. Takahashi, K. Yamagata, W. Motomura, Y. Kohgo, An inverse correlation between serum leptin levels and hemoglobin A1c in patients with non-insulin dependent diabetes mellitus 43, 187  
 Motomura, W., see Moriya, M. 43, 187
- Nakamura, Y., see Isotani, H. 43, 173  
 Nakazawa, T., see Fukuzawa, M. 43, 147  
 Narayan, K.M.V., see Chen, K.T. 43, 101  
 Neidlein, R., see Degenhardt, T.P. 43, 81  
 Nesbit, J., see Florkowski, C.M. 43, 199  
 Ng, W.Y., A.C. Thai, K.F. Lui, P.P.B. Yeo, J.S. Cheah, Systemic levels of cytokines and GAD-specific autoantibodies isotypes in Chinese IDDM patients 43, 127  
 Nishio, Y., see Harada, N. 43, 111  
 Norris, J.M., see Dorman, J.S. 43, 41
- Ohsawa, N., see Isotani, H. 43, 173  
 Ohta, S., see Fukuzawa, M. 43, 147  
 Okumura, T., see Moriya, M. 43, 187  
 Overmann, H., L. Heinemann, Injection-meal interval: recommendations of diabetologists and how patients handle it 43, 137
- Parker, G.N., see McGrath, N.M. 43, 205  
 Pendek, R., see Wan Nazaimoon, W.M. 43, 59  
 Pérez-Bravo, F., see Santos, J.L. 43, 143
- Qiang, X., see Fukuzawa, M. 43, 147
- Ramachandran, A., see Vijay, V. 43, 167  
 Rasat, R., see Wan Nazaimoon, W.M. 43, 59  
 Rashid Masoodi, S., see Hamid Zargar, A. 43, 67  
 Reiff, K., see Degenhardt, T.P. 43, 81  
 Reiter, R., see Degenhardt, T.P. 43, 81  
 Robson, R.A., see Dellow, W.J. 43, 91
- Sakata, Y., see Fukuzawa, M. 43, 147  
 Salleras, L., see Castell, C. 43, 33  
 Sansom, S.C., P. Mehta, D.A. Hall, Potentiating effects of hyper-osmolality and epidermal growth factor on the release of arachidonic acid in human glomerular mesangial cells 43, 21  
 Santos, J.L., D. Schaid, F. Pérez-Bravo, E. Carrasco, M. Calvillán, C. Albala, Applicability of the case-parent design in the etiological research of Type 1 diabetes in Chile and other genetically mixed populations 43, 143  
 Satoh, J., see Fukuzawa, M. 43, 147  
 Schaid, D., see Santos, J.L. 43, 143  
 Schmeltz, R., see Dorman, J.S. 43, 41  
 Scott, R., C.J. Lintott, P. Zimmet, L. Campbell, K. Bowen, T. Welborn, Will acarbose improve the metabolic abnormalities of insulin-resistant type 2 diabetes mellitus? 43, 179  
 Scott, R.S., see Florkowski, C.M. 43, 199  
 Serra, J., see Castell, C. 43, 33  
 Sheriff, I.H., see Wan Nazaimoon, W.M. 43, 59  
 Shimomura, Y., see Tayama, K. 43, 49  
 Shina, K., see Vijay, V. 43, 167  
 Singaraveloo, M., see Wan Nazaimoon, W.M. 43, 59  
 Snehalatha, C., see Vijay, V. 43, 167  
 Steenkiste, A.R., see Dorman, J.S. 43, 41  
 Stott, M.K., see Florkowski, C.M. 43, 199  
 Strange, P., see Marbury, T. 43, 155  
 Strein, K., see Degenhardt, T.P. 43, 81
- Takahashi, N., see Moriya, M. 43, 187  
 Takala, J., see Hänninen, J. 43, 121  
 Tanaka, K., see Isotani, H. 43, 173  
 Tanaka, Y., see Ikeda, T. 43, 193  
 Tayama, K., T. Inukai, Y. Shimomura, Preperitoneal fat deposition estimated by ultrasonography in patients with non-insulin-dependent diabetes mellitus 43, 49  
 Thai, A.C., see Ng, W.Y. 43, 127  
 Thorpe, S.R., see Degenhardt, T.P. 43, 81

- Toyota, T., see Fukuzawa, M. 43, 147
- Tresserras, R., see Castell, C. 43, 33
- Upton, J.D., see Florkowski, C.M. 43, 199
- Vera, E., see Yuen, V.G. 43, 9
- Vijay, V., C. Snehalatha, K. Shina, S. Lalitha, A. Ramachandran, Familial aggregation of diabetic kidney disease in Type 2 diabetes in south India 43, 167
- Vincent, T.E., S. Mendiratta, J.M. May, Inhibition of aldose reductase in human erythrocytes by vitamin C 43, 1
- Voss, E., see Degenhardt, T.P. 43, 81
- Walmsley, T.A., see Florkowski, C.M. 43, 199
- Wan Mohamad, W.B., see Wan Nazaimoon, W.M. 43, 59
- Wan Nazaimoon, W.M., I. Faridah, M. Singaraveloo, I.S. Ismail, W.B. Wan Mohamad, R. Letchuman, R. Rasat, R. Pendek, F.L. Hew, I.H. Sheriff, B.A.K. Khalid, Prevalence of glutamic acid decarboxylase antibodies amongst young Malaysian diabetics 43, 59
- Welborn, T., see Scott, R. 43, 179
- Willis, J.A., see Florkowski, C.M. 43, 199
- Yamagata, K., see Moriya, M. 43, 187
- Yeo, P.P.B., see Ng, W.Y. 43, 127
- Yuen, V.G., E. Vera, M.L. Battell, W.M. Li, J.H. McNeill, Acute and chronic oral administration of bis(maltolato)oxovanadium(IV) in Zucker diabetic fatty (ZDF) rats 43, 9
- Zimmet, P., see Scott, R. 43, 179





## Subject index of volume 43

**Acarbose;** Type 2 diabetes mellitus; Syndrome X 43, 179

**ACE;** DLCO; Pulmonary diffusing capacity; Pulmonary function disorder; ACE gene; NIDDM; Microangiopathy 43, 173

**ACE gene;** DLCO; Pulmonary diffusing capacity; Pulmonary function disorder; ACE; NIDDM; Microangiopathy 43, 173

**Advanced glycation end-products (AGE);** Albuminuria; Aminoguanidine; *N*<sup>ε</sup>-(carboxymethyl)lysine; Collagen; Pentosidine 43, 81

**Albuminuria;** Advanced glycation end-products (AGE); Aminoguanidine; *N*<sup>ε</sup>-(carboxymethyl)lysine; Collagen; Pentosidine 43, 81

**Albuminuria;** Non-insulin-dependent diabetes mellitus; Mortality; Coronary heart disease 43, 121

**Aldose reductase;** Sorbitol; Ascorbic acid; Human erythrocytes 43, 1

**Aldose reductase inhibitor;** Cardiovascular autonomic neuropathy; CV<sub>R R</sub>; Epalrestat 43, 193

**Aminoguanidine;** Advanced glycation end-products (AGE); Albuminuria; *N*<sup>ε</sup>-(carboxymethyl)lysine; Collagen; Pentosidine 43, 81

**Ascorbic acid;** Sorbitol; Aldose reductase; Human erythrocytes 43, 1

**Atherosclerosis;** Lysophosphatidylcholine; Lipid hydroperoxides; Lipid-lowering treatment; Diabetes mellitus 43, 111

**Cardiopulmonary disease;** Diabetes; Mortality; Taiwan 43, 101

**Cardiovascular autonomic neuropathy;** Aldose reductase inhibitor; CV<sub>R R</sub>; Epalrestat 43, 193

**Carnitine;** Glycine betaine; Sorbitol; Retinol binding protein; Proximal tubular dysfunction 43, 91

**Cases;** Epidemiology; Diabetes; Parents 43, 143

**Cell culture;** Mannitol; Osmolality; Phorbol ester 43, 21

**Chinese;** Glutamic acid decarboxylase antibodies; Malay; Indian 43, 59

**Collagen;** Advanced glycation end-products (AGE); Albuminuria; Aminoguanidine; *N*<sup>ε</sup>-(carboxymethyl)lysine; Pentosidine 43, 81

**Coronary heart disease;** Non-insulin-dependent diabetes mellitus; Mortality; Albuminuria 43, 121

**CV<sub>R R</sub>;** Aldose reductase inhibitor; Cardiovascular autonomic neuropathy; Epalrestat 43, 193

**Cytokines;** GADab-IgG subclass; IDDM 43, 127

**Diabetes;** Epidemiology; Cases; Parents 43, 143

**Diabetes;** Mortality; Cardiopulmonary disease; Taiwan 43, 101

- Diabetes mellitus;** Epidemiology; Prevalence; Risk factors; Impaired glucose tolerance **43, 33**
- Diabetes mellitus;** Lysophosphatidylcholine; Atherosclerosis; Lipid hydroperoxides; Lipid-lowering treatment **43, 111**
- Diabetes mellitus;** Morbidity; Mortality **43, 67**
- Diabetic kidney disease;** Familial aggregation; Type 2 diabetes; Nephropathy **43, 167**
- Diabetic Triopathy;** Visceral fat; Insulin; Leptin; NIDDM **43, 49**
- DLCO;** Pulmonary diffusing capacity; Pulmonary function disorder; ACE; ACE gene; NIDDM; Microangiopathy **43, 173**
- Epalrestat;** Aldose reductase inhibitor; Cardiovascular autonomic neuropathy; CV<sub>RR</sub> **43, 193**
- Epidemiology;** Diabetes; Cases; Parents **43, 143**
- Epidemiology;** Diabetes mellitus; Prevalence; Risk factors; Impaired glucose tolerance **43, 33**
- Epidemiology;** Type 1 diabetes; Insulin-dependent diabetes mellitus (IDDM); Spontaneous abortion; Pregnancy; Risk factors **43, 41**
- Familial aggregation;** Diabetic kidney disease; Type 2 diabetes; Nephropathy **43, 167**
- GADab-IgG subclass;** Cytokines; IDDM **43, 127**
- Glibenclamide;** TNF- $\alpha$ ; Gliclazide; Troglitazone; Insulin resistance **43, 147**
- Gliclazide;** TNF- $\alpha$ ; Troglitazone; Glibenclamide; Insulin resistance **43, 147**
- Glucose-lowering;** Hyperinsulinemia; Pancreatic reserves; Vanadium; Zucker diabetic fatty rat **43, 9**
- Glutamic acid decarboxylase antibodies;** Malay; Chinese; Indian **43, 59**
- Glyburide;** Oral hypoglycemic agents; Phase III study; Repaglinide; Type 2 diabetes **43, 155**
- Glycine betaine;** Sorbitol; Carnitine; Retinol binding protein; Proximal tubular dysfunction **43, 91**
- Haemochromatosis gene;** Type 2 diabetes mellitus **43, 199**
- HbA1c;** Leptin; NIDDM **43, 187**
- Human erythrocytes;** Sorbitol; Aldose reductase; Ascorbic acid **43, 1**
- Hyperinsulinemia;** Glucose-lowering; Pancreatic reserves; Vanadium; Zucker diabetic fatty rat **43, 9**
- IDDM;** Cytokines; GADab-IgG subclass **43, 127**
- Impaired glucose tolerance;** Diabetes mellitus; Epidemiology; Prevalence; Risk factors **43, 33**
- Indian;** Glutamic acid decarboxylase antibodies; Malay; Chinese **43, 59**
- Insulin;** Visceral fat; Leptin; Diabetic Triopathy; NIDDM **43, 49**
- Insulin-dependent diabetes mellitus (IDDM);** Type 1 diabetes; Spontaneous abortion; Pregnancy; Risk factors; Epidemiology **43, 41**
- Insulin resistance;** TNF- $\alpha$ ; Gliclazide; Troglitazone; Glibenclamide **43, 147**
- Intensified insulin therapy;** Type 1 diabetes mellitus; Quality of treatment; Metabolic control **43, 137**
- Leptin;** NIDDM; HbA1c **43, 187**
- Leptin;** Visceral fat; Insulin; Diabetic Triopathy; NIDDM **43, 49**
- Lipid hydroperoxides;** Lysophosphatidylcholine; Atherosclerosis; Lipid-lowering treatment; Diabetes mellitus **43, 111**
- Lipid-lowering treatment;** Lysophosphatidylcholine; Atherosclerosis; Lipid hydroperoxides; Diabetes mellitus **43, 111**
- Lysophosphatidylcholine;** Atherosclerosis; Lipid hydroperoxides; Lipid-lowering treatment; Diabetes mellitus **43, 111**
- Malay;** Glutamic acid decarboxylase antibodies; Chinese; Indian **43, 59**
- Mannitol;** Osmolality; Phorbol ester; Cell culture **43, 21**

- Maori;** Young; New Zealand; Type 2 diabetes 43, 205
- Metabolic control;** Intensified insulin therapy; Type 1 diabetes mellitus; Quality of treatment 43, 137
- Microangiopathy;** DLCO; Pulmonary diffusing capacity; Pulmonary function disorder; ACE; ACE gene; NIDDM 43, 173
- Morbidity;** Diabetes mellitus; Mortality 43, 67
- Mortality;** Diabetes; Cardiopulmonary disease; Taiwan 43, 101
- Mortality;** Diabetes mellitus; Morbidity 43, 67
- Mortality;** Non-insulin-dependent diabetes mellitus; Coronary heart disease; Albuminuria 43, 121
- N<sup>ε</sup>-(carboxymethyl)lysine;** Advanced glycation end-products (AGE); Albuminuria; Aminoguanidine; Collagen; Pentosidine 43, 81
- Nephropathy;** Familial aggregation; Diabetic kidney disease; Type 2 diabetes 43, 167
- New Zealand;** Young; Maori; Type 2 diabetes 43, 205
- NIDDM;** DLCO; Pulmonary diffusing capacity; Pulmonary function disorder; ACE; ACE gene; Microangiopathy 43, 173
- NIDDM;** Leptin; HbA1c 43, 187
- NIDDM;** Visceral fat; Insulin; Leptin; Diabetic Triopathy 43, 49
- Non-insulin-dependent diabetes mellitus;** Mortality; Coronary heart disease; Albuminuria 43, 121
- Oral hypoglycemic agents;** Glyburide; Phase III study; Repaglinide; Type 2 diabetes 43, 155
- Osmolality;** Mannitol; Phorbol ester; Cell culture 43, 21
- Pancreatic reserves;** Glucose-lowering; Hyperinsulinemia; Vanadium; Zucker diabetic fatty rat 43, 9
- Parents;** Epidemiology; Diabetes; Cases 43, 143
- Pentosidine;** Advanced glycation end-products (AGE); Albuminuria; Aminoguanidine; N<sup>ε</sup>-(carboxymethyl)lysine; Collagen 43, 81
- Phase III study;** Glyburide; Oral hypoglycemic agents; Repaglinide; Type 2 diabetes 43, 155
- Phorbol ester;** Mannitol; Osmolality; Cell culture 43, 21
- Pregnancy;** Type 1 diabetes; Insulin-dependent diabetes mellitus (IDDM); Spontaneous abortion; Risk factors; Epidemiology 43, 41
- Prevalence;** Diabetes mellitus; Epidemiology; Risk factors; Impaired glucose tolerance 43, 33
- Proximal tubular dysfunction;** Glycine betaine; Sorbitol; Carnitine; Retinol binding protein 43, 91
- Pulmonary diffusing capacity;** DLCO; Pulmonary function disorder; ACE; ACE gene; NIDDM; Microangiopathy 43, 173
- Pulmonary function disorder;** DLCO; Pulmonary diffusing capacity; ACE; ACE gene; NIDDM; Microangiopathy 43, 173
- Quality of treatment;** Intensified insulin therapy; Type 1 diabetes mellitus; Metabolic control 43, 137
- Repaglinide;** Glyburide; Oral hypoglycemic agents; Phase III study; Type 2 diabetes 43, 155
- Retinol binding protein;** Glycine betaine; Sorbitol; Carnitine; Proximal tubular dysfunction 43, 91
- Risk factors;** Diabetes mellitus; Epidemiology; Prevalence; Impaired glucose tolerance 43, 33
- Risk factors;** Type 1 diabetes; Insulin-dependent diabetes mellitus (IDDM); Spontaneous abortion; Pregnancy; Epidemiology 43, 41
- Sorbitol;** Aldose reductase; Ascorbic acid; Human erythrocytes 43, 1
- Sorbitol;** Glycine betaine; Carnitine; Retinol binding protein; Proximal tubular dysfunction 43, 91
- Spontaneous abortion;** Type 1 diabetes; Insulin-dependent diabetes mellitus (IDDM); Pregnancy; Risk factors; Epidemiology 43, 41

- Syndrome X**; Type 2 diabetes mellitus; Acarbose 43, 179
- Taiwan**; Diabetes; Mortality; Cardiopulmonary disease 43, 101
- TNF- $\alpha$** ; Gliclazide; Troglitazone; Glibenclamide; Insulin resistance 43, 147
- Troglitazone**; TNF- $\alpha$ ; Gliclazide; Glibenclamide; Insulin resistance 43, 147
- Type 1 diabetes**; Insulin-dependent diabetes mellitus (IDDM); Spontaneous abortion; Pregnancy; Risk factors; Epidemiology 43, 41
- Type 1 diabetes mellitus**; Intensified insulin therapy; Quality of treatment; Metabolic control 43, 137
- Type 2 diabetes**; Familial aggregation; Diabetic kidney disease; Nephropathy 43, 167
- Type 2 diabetes**; Glyburide; Oral hypoglycemic agents; Phase III study; Repaglinide 43, 155
- Type 2 diabetes**; Young; New Zealand; Maori 43, 205
- Type 2 diabetes mellitus**; Acarbose; Syndrome X 43, 179
- Type 2 diabetes mellitus**; Haemochromatosis gene 43, 199
- Vanadium**; Glucose-lowering; Hyperinsulinemia; Pancreatic reserves; Zucker diabetic fatty rat 43, 9
- Visceral fat**; Insulin; Leptin; Diabetic Triopathy; NIDDM 43, 49
- Young**; New Zealand; Maori; Type 2 diabetes 43, 205
- Zucker diabetic fatty rat**; Glucose-lowering; Hyperinsulinemia; Pancreatic reserves; Vanadium 43, 9



